Clinical Trials Browser

Carcinoma, Hepatocellular

Biliary Tract Neoplasms

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Rectal Neoplasms Malignant

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Appendiceal Neoplasms, Colorectal Neoplasms

Colonic Neoplasms

Colorectal Neoplasms

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Metastasis

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

Colorectal Neoplasms

Metastatic Colorectal Cancer With Left-sided Primary Tumor

Neutropenia, Colorectal Neoplasms

Stomach Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Carcinoma, Hepatocellular

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Rectal Neoplasms

Colorectal Neoplasms

Spinocerebellar Degenerations, Colorectal Neoplasms

Colorectal Cancer Metastatic

Unresectable Metastatic Colorectal Cancer

Colorectal Neoplasms

Carcinoma, Hepatocellular

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Liver Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Neoplasm Metastasis, Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Carcinoma, Hepatocellular, Recurrence, Osteosarcoma

Rectal Neoplasms

Carcinoma, Hepatocellular

Rectal Neoplasms

Colorectal Neoplasms

Clinical Trials

MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

QLS5132 Combination Therapy in Advanced Solid Tumors

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

COLIBRI-GI

ARIEL-ENGIC

Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

REFISH

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer

Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC

BETWEEN

Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer

QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer

AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis

QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

Efficacy and Safety of Trifluridine/tipiracil (TAS-102) Combined with Bevacizumab and Putalimab in the Treatment of Patients with MCRC After Cytoreductive Surgery: a Single-arm, Single-center Clinical Study

SCRIPBOT

Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer

SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer

PHARBEVACOL

Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer

Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma

A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab

Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer

Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab

Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer

SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer

A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer

Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer

Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation

Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study